Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension
Gian Paolo Rossi,Teresa M Seccia,Matthias Barton,A H Jan Danser,Peter W de Leeuw,Neeraj Dhaun,Damiano Rizzoni,Patrick Rossignol,Luis-Miguel Ruilope,Anton H van den Meiracker,Sadayoshi Ito,Naoyuki Hasebe,David J Webb,Seccia, Teresa M.,de Leeuw, Peter W.,Barton, Matthias,Rizzoni, Damiano,Danser, A.H. Jan,Dhaun, Neeraj,Webb, David J.,Ruilope, Luis-Miguel,Rossignol, Patrick,Rossi, Gian Paolo,Ito, Sadayoshi,van den Meiracker, Anton H.,Hasebe, Naoyuki
DOI: https://doi.org/10.1097/HJH.0000000000001600
IF: 4.9
2019-10-03
Journal of Hypertension
Abstract:After examining in Part I the general mechanisms of endothelial cell injury in the kidney, the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension and the Japanese Society of Hypertension will herein review current knowledge on the role of endothelial dysfunction in multiple disease conditions that affect the kidney, including diabetes mellitus, preeclampsia, solid organ transplantation, hyperhomocysteinemia and antiangiogenic therapy in cancer. The few available randomized controlled clinical trials specifically designed to evaluate strategies for correcting endothelial dysfunction in patients with hypertension and/or chronic kidney disease are also discussed alongside their cardiovascular and renal outcomes.
peripheral vascular disease